← Back to graph
Prescription

dulaglutide

Selected indexed studies

  • Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. (Lancet, 2019) [PMID:31189511]
  • Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. (Lancet Diabetes Endocrinol, 2018) [PMID:29397376]
  • Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. (Am Heart J, 2024) [PMID:37758044]

_Worker-drafted node — pending editorial review._

Connections

dulaglutide is a side effect of

Sources

Local graph